ACET Shares Outstanding History
Below is a table of the ACET shares outstanding history going back to 2/2/2010:

Date ACET Shares Outstanding
2/2/20103.61M
5/3/20103.63M
9/3/20103.63M
11/2/20103.64M
2/1/20113.80M
5/2/20113.80M
9/2/20113.81M
11/1/20113.82M
2/3/20123.83M
5/1/20123.83M
9/4/20123.87M
11/6/20123.88M
2/4/20133.90M
5/6/20133.91M
8/23/20134.01M
11/1/20134.02M
2/3/20144.05M
5/5/20144.10M
9/2/20144.14M
11/3/20144.15M
2/2/20154.16M
5/4/20154.16M
9/8/20154.19M
11/2/20154.21M
2/1/20164.22M
5/2/20164.23M
8/22/20164.24M
11/1/20164.29M
2/1/20174.30M
5/1/20174.30M
8/21/20174.30M
10/31/20174.38M
1/30/20184.39M
5/1/20184.40M
9/13/20184.40M
10/15/20184.40M
11/5/20184.40M
2/12/20194.41M
9/16/202019.59M
11/3/202019.60M
3/10/202131.78M
5/12/202131.81M

Also see: ACET Market Cap History
ACET YTD Return
ACET Historical Shares Outstanding:
+21.28% CAGR
ACET Historical Shares Outstanding: +21.28% CAGR

Mouse over chart for data details
2/2/2010 ...5/12/2021
Adicet Bio is a clinical-stage biopharmaceutical company developing medicines that target the biology of aging to prevent or treat age-related diseases with the potential to extend healthy lifespan. Co.'s main program selectively inhibits the target of rapamycin complex 1 (TORC1), a conserved pathway that contributes to the age-related decline in function of multiple organ systems. Co.'s product candidate, RTB101, is an oral and selective inhibitor of TORC1. RTB101 inhibits the phosphorylation of multiple targets downstream of TORC1. Co. has licensed the rights to its TORC1 program, including RTB101 alone or in combination with everolimus, from Novartis International Pharmaceutical Ltd. We show 42 historical shares outstanding datapoints in our coverage of ACET's shares outstanding history.

Understanding the changing numbers of ACET shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like ACET versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching ACET by allowing them to research ACET shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes
Get Free SEC filing alerts for ACET:
ACET SEC Filing Email Alerts ServiceExternal link
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Aceto (ACET) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

ACHC Shares Outstanding History
ACHN Shares Outstanding History
ACHV Shares Outstanding History
ACOR Shares Outstanding History
ACRS Shares Outstanding History
ACRX Shares Outstanding History
ACST Shares Outstanding History
ADMA Shares Outstanding History
ADMP Shares Outstanding History
ADMS Shares Outstanding History
More Healthcare companies »

 

ACET Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2021, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.